Industry Profile: OptosSeptember 18, 2012
Optos plc has the vision to be THE retina company. We aim to be recognized as a leading provider of devices to eye care professionals for improved patient care. Optos’ core devices produce ultra-widefield, high-resolution digital images (optomap®) of approximately 82 percent of the retina, something no other device is capable of doing in any one image. Our recent acquisition of OPKO instrumentation brings optical coherence tomography (OCT) diagnostic devices and optical ultrasound scanners, used in the diagnosis and management of eye disease and conditions.
Optos’ ultra-widefield retinal imaging technology, combined with the specific data that can be derived from OCT images, has the potential to offer optometrists the most powerful tools for disease diagnosis and management. The optomap images provide enhanced clinical information, which facilitates the early detection and management of disorders and diseases evidenced in the retina such as retinal detachments and tears, diabetic retinopathy and age-related macular degeneration. Retinal imaging can also indicate evidence of non-eye or systemic diseases such as hypertension and certain cancers. OCT delivers an image that shows a three-dimensional, cross-sectional view of the retina in any particular area, typically in the central pole area of the retina around the optic nerve and macula and is used to detect the presence of and understand the severity of disease.
The newest product is Daytona, a tabletop model with new easy-to-use image capture software. Daytona produces optomap ultra-widefield digital retinal imaging procedures to support wellness screening and diagnostic examinations as well as the optomap af ultra-widefield autofluorescence imaging to provide additional clinical data.
Exploring the frontiers and vast potential of retinal medicine, more than 50 papers utilizing Optos retinal imaging technology were presented at the 2012 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Fort Lauderdale, Fla. These clinical studies represent experience with ultra-widefield imaging in more than 3,000 patients from 10 countries and explore the utility of ultra-wide field and OCT technology in 25 different eye diseases.
Optos’ CEO Roy Davis said, “These results underpin our vision to drive our clinical evidence even further. We are now demonstrating to clinicians the ability to see more, refer more, and treat more and importantly to understand more about the extent of eye disease. Further studies are already under way with leading Investigators and with pharmaceutical companies to validate our findings.”
A clinical validation study comparing Optos ultra-widefield imaging to Early Treatment Diabetic Retinopathy Study (ETDRS) protocol fundus photography, the gold standard for assessing severity of diabetic retinopathy, was recently completed by the Joslin Diabetes Center and published in the American Journal of Ophthalmology.
ETDRS protocol seven standard-field 30-degree color fundus photography has long been the imaging benchmark for assessing diabetic retinopathy severity. This study reports that Optos’ ultra-widefield non-dilated optomap images compared favorably with dilated ETDRS photos and dilated retinal examination by a retinal specialist in determining clinical severity of diabetic retinopathy and diabetic macular edema.
For more information about the company or products, visit optos.com.